Abbott Laboratories (ABT)

From the record

Abbott Laboratories' filings since 2017 show 6 warning events: a debt default or acceleration notice (8-K item 2.04, 6 times, the latest 2019-12-19) (its current reports).

From the record

Abbott Laboratories' 10 filed years say what it did: revenue went from $21 billion in fiscal 2016 to $44 billion in fiscal 2025, up 8.7% a year; it rose in 8 of 9 years; the deepest fall was 8% from fiscal 2022 to fiscal 2023; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Abbott Laboratories' diluted share count shrank about 0.3% a year, and dividends and buybacks returned about 59% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 12 sales and 6 purchases of their own stock on the open market in the year to 2026-11-06, buying about $4 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Abbott Laboratories earned about 12 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 29 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 39 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).

From the record

Abbott Laboratories' standing among 315 graded names in its industry family: revenue of $44 billion in fiscal 2025 ranks in the top 3% by size; a net margin of 14.7% ranks in the top 14%; revenue growth of 0.5% a year over the last 3 filed years ranks in the bottom 40% (its annual reports).

From the record

Abbott Laboratories' leadership, from its insiders' filings and its current reports: the chief executive on the record is Ford, Robert B (CHAIRMAN AND CEO, as filed), filing under that title since 2020-05-22, 6.5 years (top 33% of its family); the 24 officers and directors filing in the last fifteen months have been on the record a median of 6.9 years (top 28%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 24 people in charge now (top 17%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Abbott Laboratories' room to grow, from the newest filed statements (fiscal 2025): cash of $8.5 billion against debt of $9.9 billion leaves -1.6% of its assets as net cash, bottom 12% of its family; cash from operations less capital spending is 16.7% of revenue (top 17%); a gross margin of 56.4% (bottom 33%); research spending of 6.6% of revenue (bottom 8%) (its annual report).

From the record

Abbott Laboratories' growth drivers, from the filed years to fiscal 2025: revenue grew 0.5% a year over the last three filed years against 8.7% over all 10, slowing (bottom 39% of its family); the newest year grew 5.7% (bottom 47%); research spending grew 0.6% a year (bottom 49%); capital spending grew 6.9% a year (top 32%) (its annual reports). Abbott Laboratories reported 4 lines of business in fiscal 2025: Medical Devices at $21 billion, Diagnostic Products at $8.9 billion, Nutritional Products at $8.5 billion, and 1 more. 3 of 4 grew in the latest filed year, and the largest line is 48% of revenue (its annual report).

From the record

Abbott Laboratories' newest year against its own record: revenue of $44 billion in fiscal 2025 came in 7.8% above the $41 billion its prior three years' pace pointed to (top 36% of its family); net income of $6.5 billion against a prior three-year average of $8.7 billion (bottom 31%); a net margin of 14.7% against 20.7% before (bottom 31%) (its annual reports).